Glucagon-like peptide 1 (GLP-1)

T.D. Müller; B. Finan; S.R. Bloom; D. D'Alessio; D.J. Drucker; P.R. Flatt; A. Fritsche; F. Gribble; H.J. Grill; J.F. Habener; J.J. Holst; W. Langhans; J.J. Meier; M.A. Nauck; D. Perez-Tilve; A. Pocai; F. Reimann; D.A. Sandoval; T.W. Schwartz; R.J. Seeley; K. Stemmer; M. Tang-Christensen; S.C. Woods; R.D. DiMarchi; M.H. Tschöp

Molecular Metabolism (Dec 2019)

Glucagon-like peptide 1 (GLP-1)

T.D. Müller,
B. Finan,
S.R. Bloom,
D. D'Alessio,
D.J. Drucker,
P.R. Flatt,
A. Fritsche,
F. Gribble,
H.J. Grill,
J.F. Habener,
J.J. Holst,
W. Langhans,
J.J. Meier,
M.A. Nauck,
D. Perez-Tilve,
A. Pocai,
F. Reimann,
D.A. Sandoval,
T.W. Schwartz,
R.J. Seeley,
K. Stemmer,
M. Tang-Christensen,
S.C. Woods,
R.D. DiMarchi,
M.H. Tschöp

Affiliations

T.D. Müller: Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, Tübingen, Germany; Corresponding author. Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
B. Finan: Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA
S.R. Bloom: Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
D. D'Alessio: Division of Endocrinology, Duke University Medical Center, Durham, NC, USA
D.J. Drucker: The Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Ontario, M5G1X5, Canada
P.R. Flatt: SAAD Centre for Pharmacy & Diabetes, Ulster University, Coleraine, Northern Ireland, UK
A. Fritsche: German Center for Diabetes Research (DZD), Neuherberg, Germany; Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, Department of Internal Medicine, University of Tübingen, Tübingen, Germany
F. Gribble: Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK
H.J. Grill: Institute of Diabetes, Obesity and Metabolism, Department of Psychology, University of Pennsylvania, Philadelphia, PA, 19104, USA
J.F. Habener: Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Harvard University, Boston, MA, USA
J.J. Holst: Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
W. Langhans: Physiology and Behavior Laboratory, ETH Zurich, Schwerzenbach, Switzerland
J.J. Meier: Diabetes Division, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany
M.A. Nauck: Diabetes Center Bochum-Hattingen, St Josef Hospital (Ruhr-Universität Bochum), Bochum, Germany
D. Perez-Tilve: Department of Internal Medicine, University of Cincinnati-College of Medicine, Cincinnati, OH, USA
A. Pocai: Cardiovascular & ImmunoMetabolism, Janssen Research & Development, Welsh and McKean Roads, Spring House, PA, 19477, USA
F. Reimann: Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK
D.A. Sandoval: Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA
T.W. Schwartz: Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, DL-2200, Copenhagen, Denmark; Department of Biomedical Sciences, University of Copenhagen, DK-2200, Copenhagen, Denmark
R.J. Seeley: Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA
K. Stemmer: Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
M. Tang-Christensen: Obesity Research, Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark
S.C. Woods: Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA
R.D. DiMarchi: Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA; Department of Chemistry, Indiana University, Bloomington, IN, USA
M.H. Tschöp: German Center for Diabetes Research (DZD), Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany; Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

Journal volume & issue: Vol. 30
pp. 72 – 130

Abstract

Read online

Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders Keywords: GLP-1, Insulin, Glucagon, Diabetes, Obesity, Incretin

Published in Molecular Metabolism

ISSN: 2212-8778 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine
Website: https://www.journals.elsevier.com/molecular-metabolism/

About the journal